Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 23: SUPER LIPID
Author(s): Alexander Fanaroff Added: 2 years ago
AHA 2023 — We are joined by Dr Alexander Fanaroff (Penn Medicine, US) to discuss the findings from a cluster randomised trial of automated referral to centralised pharmacy services for evidence-based statin initiation in high-risk patients.Gaps have been observed in evidence-based statin prescriptions, where more than 50% of US adults with an indication for atherosclerotic cardiovascular disease… View more

Prevention & Chronic Conditions
AHA 24: New Insights from CLEAR OUTCOMES
Author(s): Marc P Bonaca Added: 1 year ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,… View more

Vascular Disease and Surgery

Prevention & Chronic Conditions
ESC 25: The NEWTON-CABG CardioLink-5 Study
Author(s): Subodh Verma Added: 5 months ago
ESC Congress 2025 - NEWTON-CABG finds evolocumab with regular statin therapy did not improve vein graft patency after coronary artery bypass graft (CABG) surgery in the short-term.Dr Subodh Verma and Dr Lawrence Leiter (University of Toronto, Toronto, CA) join us to discuss findings from NEWTON-CABG CardioLink-5 (NCT03900026). The investigator-initiated multicenter, randomised, placebo-controlled… View more

Intervention
ESC 23: LODESTAR Trial
Author(s): Myeong-Ki Hong Added: 2 years ago
ESC 23 — Dr Myeong-Ki Hong (Yonsei University College of Medicine, KR) outlines the late-breaking results from the LODESTAR trial (NCT02579499). LODESTAR (Yonsei University) was a randomized, open-label multicenter trial that aimed to compare the clinical efficacy and safety of atorvastatin vs rosuvastatin for the secondary prevention of coronary artery disease. 4400 coronary artery disease… View more

Prevention & Chronic Conditions
Transforming Outcomes with Lipid Clinics in Malaysia: Enablers and Barriers for the Implementation of Multidisciplinary Approach Clinics for the Management of Dyslipidaemia
Author(s): Azhari Rosman , Ahmad Khairuddin Mohamed Yusof , Hafidz Abd Hadi , et al Added: 1 month ago

Prevention & Chronic Conditions
Post-ACS Discharge and Long-term Follow-up Recommendations for Thailand
Author(s): Rungroj Krittayaphong , Wacin Buddhari , Bancha Sookananchai , et al Added: 10 months ago

Intervention

MI/ACS
AHA 23: 3 Trials That Will Change My Practice
Author(s): Purvi Parwani Added: 2 years ago
AHA 23 — Dr Purvi Parwani, cardiologist and multimodality imager, and director of the Women's Heart Clinic at Loma Linda University Health in the US, spotlights three game-changing late-breaking science trials from the AHA Scientific Sessions. Discover the trials anticipated to reshape clinical practices as Dr Parwani shares her insights.Trials discussed in detail include:POP-HT: Cardiac… View more

Guidelines & Statements

Prevention & Chronic Conditions
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 2 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 10 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions